{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:51:35Z","timestamp":1777179095271,"version":"3.51.4"},"reference-count":4,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>The alpha\u2010herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard\u2010of\u2010care (SoC) is based on nucleoside analogs (NAs), which require specific activation in infected cells. These existing drugs exhibit substantial limitations, warranting the development of new and more effective drugs.<\/jats:p>","DOI":"10.1002\/cpt.647","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T08:22:48Z","timestamp":1486196568000},"page":"30-32","source":"Crossref","is-referenced-by-count":9,"title":["Drugs in development for herpes simplex and varicella zoster virus"],"prefix":"10.1111","volume":"102","author":[{"given":"A","family":"Birkmann","sequence":"first","affiliation":[{"name":"AiCuris Anti\u2010infective Cures GmbH Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures GmbH Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"e_1_2_7_1_1","unstructured":"Thomson Cortellis. <https:\/\/cortellis.thomsonreuterslifesciences.com\/ > searched for \u201cherpes\u201d with filters applied: Clinical; Phase 1 Clinical; Phase 2 Clinical; Phase 3 Clinical; Pre\u2010registration; active indications: \u201cAdult varicella zoster virus infection\u201d; \u201cDNA virus infection\u201d; \u201cHSV\u20102 infection\u201d; \u201cHerpes simplex virus infection\u201d; \u201cHerpesvirus infection\u201d; \u201cHerpetic keratitis\u201d; \u201cVaricella zoster virus infection\u201d; \u201cViral infection\u201d;2016."},{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-405880-4.00004-4"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.04.012"},{"key":"e_1_2_7_4_1","unstructured":"Gupta S.FDA Grants N\u2010Methanocarbathymidine Orphan Drug Designation2016. <http:\/\/www.infectiousdiseaseadvisor.com\/treatments\/orphan\u2010drug\u2010designation\u2010for\u2010n\u2010methanocarbathymidine\/article\/526595\/>."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:35:10Z","timestamp":1699364110000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/cpt.647"],"URL":"https:\/\/doi.org\/10.1002\/cpt.647","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}